Cancer Research · 2010 · 59 citations · 19 references
MedicineOncologyPharmacologyMetastasisMolecular OncologyTumor MicroenvironmentAngiogenesisAngiogenesis In CancerGrowth Factor SignalingLiver MetastasisMetastatic Signaling PathwaysRenal Cell CarcinomaTumor Angiogenesis SignalingTumor Microenvironment RegulationVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor InhibitorsVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsVegfr Inhibitors
Tumors induce new blood vessel growth primarily from host organ microvascular endothelial cells (EC), and microvasculature differs significantly between the lung and liver. Vascular endothelial growth factor (VEGF or VEGF-A) promotion of tumor angiogenesis is thought to be mediated primarily by VEGF receptor-2 (VEGFR-2). In this study, VEGFR-2 antibody (DC101) inhibited growth of RenCa renal cell carcinoma lung metastases by 26%, whereas VEGFR-1 antibody (MF-1) had no effect. However, VEGFR-2 neutralization had no effect on RenCa liver metastases, whereas VEGFR-1 neutralization decreased RenCa liver metastases by 31%. For CT26 colon carcinoma liver metastases, inhibition of both VEGFR-1 and VEGFR-2 was required to induce growth delay. VEGFR-1 or VEGFR-2 inhibition decreased tumor burden not by preventing the establishment of micrometastases but rather by preventing vascularization and growth of micrometastases by 55% and 43%, respectively. VEGF induced greater phosphorylation of VEGFR-2 in lung ECs and of VEGFR-1 in liver ECs. EC proliferation, migration, and capillary tube formation in vitro were suppressed more by VEGFR-2 inhibition for lung EC and more by VEGFR-1 inhibition for liver EC. Collectively, our results indicate that liver metastases are more reliant on VEGFR-1 than lung metastases to mediate angiogenesis due to differential activity of VEGFRs on liver EC versus lung EC. Thus, therapies inhibiting specific VEGFRs should consider the targeted sites of metastatic disease.
19
Peter Carmeliet, Lieve Moons, Aernout Luttun et al. · Nature Medicine · 2001 · 1.7K citations
Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens et al. · Journal of Clinical Oncology · 2010 · 557 citations · Full text
Medicine, Oncology, Pharmacology +17
Identification of an angiogenic mitogen selective for endocrine gland endothelium
Jennifer LeCouter, Joe Kowalski, Jessica Foster et al. · Nature · 2001 · 555 citations